Safety and efficacy evaluation of a novel dietary muramidase for swine

Heliyon

Wolfgang Schliffka¹  Sabine van Cauwenberghe¹  Maria C. Walsh¹  Rual Lopez-Ulibarri¹  Heng-Xiao Zhai²  Estefania Pérez Calvo³ 

[1] DSM Nutritional Products AG, Wurmisweg 576, 4303 Kaiseraugst, Switzerland;DSM Nutritional Products China, Animal Nutrition Research Center Co., Ltd, Bazhou, Hebei Province, China 065799;DSM Nutritional Products France, Centre de Recherche en Nutrition et Santé Animale, F-68305 Saint Louis, France;

关键词: Agriculture;    Microbiology;    Toxicology;    Animal nutrition;    Agricultural policy;    Microorganism;   

DOI  :  

来源: DOAJ

【 摘 要 】

The safety of a novel microbial muramidase (Muramidase 007) as a feed additive for swine was evaluated in a target animal safety study (Experiment 1). Forty weanling pigs were allotted to 4 dietary treatments: T1 control group, and 3 groups receiving Muramidase 007 in increasing doses: T2 65,000 (1X), T3 325,000 (5X) and T4 650,000 (10X) LSU(F)/kg feed. The efficacy of Muramidase 007 on growth performance was evaluated in a feeding experiment (Experiment 2). A total of 288 piglets were allotted to two groups: T1 control group and T2 receiving Muramidase 007 at 50,000 (LSU(F)/kg feed. In Experiment 1, no growth depression of pigs was observed. No adverse effects of Muramidase 007 were observed for any of the hematology and serum chemistry parameters measured or on pig health status. Post-mortem evaluation showed no adverse effects due to Muramidase 007 supplementation in the gross pathology or in the histological examination. In Experiment 2, Muramidase 007 significantly increased overall (d 0–42) average daily gain (ADG) and tended to improve overall average daily feed intake (ADFI) and day 42 body weight of nursery pigs and had no effect on feed conversion ratio (FCR). Overall, results of these studies show that there were no adverse effects of Muramidase 007 compared to the control group.

【 授权许可】

Unknown